Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Plosaracetam is a compound belonging to the racetam family of nootropics, characterized by a pyrrolidone nucleus. While it is frequently listed in chemical databases and nootropic compendiums alongside better-known analogs like piracetam and pramiracetam, there is a significant lack of peer-reviewed clinical data or formal pharmacological characterization for this specific entity. Like other members of the racetam class, it is theoretically proposed to act as a cognitive enhancer or neuroprotective agent, potentially modulating neurotransmitter systems such as the cholinergic or glutamatergic pathways. However, it has not reached the stage of formal clinical development for any primary indication, and its status remains largely restricted to theoretical or early-stage chemical research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on plosaracetam.